No Data
No Data
Relmada Therapeutics Shifts Focus After Study Discontinuation
Relmada Therapeutics Exploring Sale After Lead Program Failure
Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives
Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives
Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017